🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the UK / NCT05264389
Active, not recruiting Observational

Post-market Clinical Follow-up (PMCF) Study of the Poly-Tape Devices for Medial Patellofemoral Ligament (MPFL) Reconstruction

NCT05264389 · tracked via the Priya Life Science UK tracker
Sponsor
Xiros Ltd
Phase
Observational
Started
2022-09-05
Last updated
2026-05-15

Condition(s) studied

Medial Patellofemoral Dislocation

Investigational drug(s) / intervention(s)

Poly-Tape Devices

Poly-Tape Devices: Poly-Tape Devices, 10mm Poly-Tape or 5mm Infinity-Lock Tape, for Medial Patellofemoral Ligament (MPFL) Reconstruction

Study summary

This is a Post Market Clinical Follow Up Study in Orthopaedics. It will verify the long-term safety and performance of the device in the intended patient population, when indicated for the reconstruction of a ligament in the kneecap - the Medial Patellofemoral Ligament (MPFL).

The Medical Devices in this study, 10mm Poly-Tape and 5mm Infinity-Lock Tape, are Class III CE-Marked devices manufactured by Xiros Ltd. Both devices fall under the Poly-Tape family. Poly-Tapes are single-use devices, they are indicated for patients requiring soft tissue approximation and reconstruction of ligaments and tendons. The device can be fixed to the bone using several different methods, including screws.

This study is a prospective, multicentre, consecutively recruited non-randomised study. The total length of the study is expected to be 7 years. This includes a recruitment period of approximately 24 months and a 5-year follow-up. A total of 59 subjects will be enrolled into the study with follow up at 6 weeks, 6 months, 1 year, 2 years and 5 years in clinic and by questionnaires. All subjects treated with either the 10mm Poly-Tape or 5mm Infinity-Lock Tape for MPFL reconstruction, will be consecutively recruited into the study.

Eligibility

Sex
ALL
Min age
13 Years
Max age
Healthy volunteers
No
Inclusion Criteria: Patient must be 13 years old or above. Patients who require MPFL reconstruction. Patients willing to participate in the study and have been informed of the nature of the study, agree to its follow-up and have provided written informed consent as approved by the Research Ethics Committee (REC). Exclusion Criteria: These devices should not be used in procedures which bridge, disturb, or disrupt the growth plate in immature patients since they will not elongate as the patient grows. Patients known to be hypersensitive to titanium alloy or polyester. Appropriate tests should be carried out on patients with suspected material sensitivity prior to implantation. Patients with any infections or structural or pathological condition of the bone or soft tissue that would be expected to impair healing or secure fixation. Bone quality should be assessed prior to surgery. Patients who are unable or unwilling to restrict activities to prescribed levels or to follow the rehabilitation instructions during the healing period. Patients for whom the implantation is intended to be non-permanent, since they integrate well with the patient's tissue.

Primary outcome measure(s)

Trial sites (5)

FacilityCityRegionStatus
James Paget University Hospitals NHS Foundation Trust Great Yarmouth United Kingdom
Tameside and Glossop Integrated Care NHS Foundation Trust Manchester United Kingdom
University of North Midlands NHS Trust Stoke-on-Trent United Kingdom
Hampshire Hospitals NHS Foundation Trust Winchester United Kingdom
Somerset NHS Foundation Trust Yeovil United Kingdom
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05264389 on ClinicalTrials.gov ↗ ← All trials in the UK